IP Library Assignment 057354/0120
Patent Assignment
Reel/Frame 057354/0120

Change of Name

Recorded: 2021-08-30 Pages: 4
Assignor
ORFAN BIOTECH INC.
Executed: 2021-08-10
Assignee
CANTERO THERAPEUTICS, INC.
421 KIPLING STREET, PALO ALTO, CALIFORNIA, 94301
Covered Properties (3)
Triazole Glycolate Oxidase Inhibitors
Application: 17/255,600 →
Publication: US 2021/0403439
Triazole Glycolate Oxidase Inhibitors
Application: 62/694,918 →
Triazole Glycolate Oxidase Inhibitors
Application: 62/827,573 →
Related Assignments (5)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Jul 24, 2018
From: MAAG, HANS; FERNANDES, MIGUEL XAVIER; ZAMBONI, ROBERT; AKBARIROMANI, ELHAM
To: ORFAN BIOTECH INC.
Reel/Frame 046448/0120 →
Assignment of Assignor's Interest May 22, 2019
From: MAAG, HANS; FERNANDES, MIGUEL XAVIER; ZAMBONI, ROBERT; AKBARIROMANI, ELHAM
To: ORFAN BIOTECH INC.
Reel/Frame 049254/0601 →
Security Interest Jan 17, 2024
From: CALCILYTIX THERAPEUTICS INC.; ADRENAS THERAPEUTICS INC.; PHOENIX TISSUE REPAIR, INC.; NAVIRE PHARMA, INC.
To: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 066342/0154 →
Security Interest Jan 19, 2024
From: BRIDGEBIO PHARMA, INC.; QED THERAPEUTICS, INC.; EIDOS THERAPEUTICS, INC.; THERAS, INC.
To: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 066355/0126 →
Release of Security Interest in Patent Collateral Mar 5, 2025
From: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
To: BRIDGEBIO PHARMA, INC.; QED THERAPEUTICS, INC.; EIDOS THERAPEUTICS, INC.; ML BIO SOLUTIONS INC.
Reel/Frame 070551/0095 →